Honestly, that press release didn't really go into any detail at all. I can see why you called it weak wording ( and certainly AGREE ). It also being on March 9, 2016 vs. one or two weeks later plays into results on Fispemifene possibly not being ready to be released. The End of Year Conference Call would be an Excellent opportunity for them to go in depth in order to explain the Fispemifene results and what this means going forward for the company. I still think there is a possibility that they release results this following Monday. But the chances of that "feel" less likely.
Another thing, we all know that Vitaros sales have increased from 3Q 2015 to 4Q 2015. And if we didn't know this information before hand, we could make the same argument, that the sales must be stagnant, because the press release did not mention anything in regards to this ( weak press release ). I know it might not seem like much - but we already know that sales have increased in Europe by 22% between the 3Q Unit Sales ( the revised amount * ) and the 4Q Unit Sales.
* As I mentioned on a previous post. 3Q Vitaros Units were previously revised up by 85,000 Units ( previously reported sales of Vitaros units during the 3Q were 183,000 units ). That in itself was a 46% increase. They sold 268,500 Vitaros units during the 3Q 2015.
Why would this information be important for this press release? We should have received royalties for the above mentioned Vitaros units sales and should be reported during this Conference Call. It is actually a 153% increase in Vitaros units sold when you compare it to 2Q 2015 unit sales.
Going back to the 4Q Sales figures - during the last Presentation, they had Vitaros unit sales at 325,464 for the quarter. Richard Pascoe did mention that these numbers were not final. He mentioned Takeda sales not being included and I also believe he was talking in plural ( meaning more than one partner still to completely report ).
Judging by the press release, and it's lack of detail, you would think that nothing is happening. Vitaros sales were not Increasing significantly Quarter over Quarter - all of 2015! Not to mention pending Fispemifene results due! |
